PharmaShots | Incisive News in 3 Shots

Subscribe Now

dupilumab

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

Sanofi Reports Results of Dupixent (dupilumab) in P-III LIBERTY ASTHMA VOYAGE Study in Children with Asthma

October 13, 2020

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

Sanofi's Dupixent (dupilumab) Receives the Health Canada Approval for Severe Chronic Rhinosinusitis with Nasal Polyposis

August 19, 2020

Sanofi's Dupixent (dupilumab) Receives the US FDA's Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Severe Atopic Dermatitis

Sanofi's Dupixent (dupilumab) Receives the US FDA's Approval as First Biologic for Children Aged 6-11 Years with Moderate-to-Sever...

May 27, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us